151 related articles for article (PubMed ID: 31913714)
1. Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models.
Gong J; Guo F; Cheng W; Fan H; Miao Q; Yang J
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):408-414. PubMed ID: 31913714
[TBL] [Abstract][Full Text] [Related]
2. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.
Wang R; Li L; Duan A; Li Y; Liu X; Miao Q; Gong J; Zhen Y
Cancer Lett; 2019 Apr; 448():84-93. PubMed ID: 30742941
[TBL] [Abstract][Full Text] [Related]
4. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.
Shen Y; Yang T; Cao X; Zhang Y; Zhao L; Li H; Zhao T; Xu J; Zhang H; Guo Q; Cai J; Gao B; Yu H; Yin S; Song R; Wu J; Guan L; Wu G; Jin L; Su Y; Liu Y
MAbs; 2019; 11(6):1149-1161. PubMed ID: 31161871
[TBL] [Abstract][Full Text] [Related]
5. Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies.
Dietlein M; Börner SM; Fischer T; Hansen H; Schnell R; Zimmermanns B; Tawadros S; Engert A; Staak O; Pogge von Strandmann E; Kobe C; Schicha H; Schomäcker K
Nuklearmedizin; 2010; 49(3):97-105. PubMed ID: 20126826
[TBL] [Abstract][Full Text] [Related]
6. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
7. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
Zhang M; Yao Z; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Janik J; Brechbiel MW; Waldmann TA
Blood; 2006 Jul; 108(2):705-10. PubMed ID: 16551968
[TBL] [Abstract][Full Text] [Related]
8. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines.
Heuck F; Ellermann J; Borchmann P; Rothe A; Hansen H; Engert A; von Strandmann EP
J Immunother; 2004; 27(5):347-53. PubMed ID: 15314543
[TBL] [Abstract][Full Text] [Related]
9. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
Hübinger G; Scheffrahn I; Müller E; Bai R; Duyster J; Morris SW; Schrezenmeier H; Bergmann L
Exp Hematol; 1999 Dec; 27(12):1796-805. PubMed ID: 10641597
[TBL] [Abstract][Full Text] [Related]
10. CD30 as a therapeutic target for lymphoma.
Schirrmann T; Steinwand M; Wezler X; Ten Haaf A; Tur MK; Barth S
BioDrugs; 2014 Apr; 28(2):181-209. PubMed ID: 24043362
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood.
Tomaszewski MM; Moad JC; Lupton GP
J Am Acad Dermatol; 1999 May; 40(5 Pt 2):857-61. PubMed ID: 10321635
[TBL] [Abstract][Full Text] [Related]
12. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
13. Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells.
Suzuki O; Hirsch B; Abe M; Dürkop H; Stein H
Lab Invest; 2012 Feb; 92(2):191-9. PubMed ID: 21986812
[TBL] [Abstract][Full Text] [Related]
14. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
15. Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation.
Dürkop H; Hirsch B; Hahn C; Foss HD; Stein H
J Pathol; 2003 Jun; 200(2):229-39. PubMed ID: 12754742
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD30 in anaplastic large cell lymphoma.
Vadakara J; Pro B
Curr Hematol Malig Rep; 2012 Dec; 7(4):285-91. PubMed ID: 23065407
[TBL] [Abstract][Full Text] [Related]
17. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
Renner C; Stehle I; Lee FT; Hall C; Catimel B; Nice EC; Mountain A; Rigopoulos A; Brechbiel MW; Pfreundschuh M; Scott AM
Cancer Immunol Immunother; 2001 Apr; 50(2):102-8. PubMed ID: 11401024
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.
Molavi O; Xiong XB; Douglas D; Kneteman N; Nagata S; Pastan I; Chu Q; Lavasanifar A; Lai R
Biomaterials; 2013 Nov; 34(34):8718-8725. PubMed ID: 23942212
[TBL] [Abstract][Full Text] [Related]
19. Primary gastric CD30 (Ki-1)-positive large cell non-Hodgkin's lymphomas. A clinicopathologic analysis of six cases.
Paulli M; Rosso R; Kindl S; Boveri E; Bonoldi E; Stracca V; Motta T; Arrigoni G; Lazzarino M; Menestrina F
Cancer; 1994 Feb; 73(3):541-9. PubMed ID: 8299075
[TBL] [Abstract][Full Text] [Related]
20. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
